ICN 16967
Alternative Names: Anti-CD44 oligonucleotide - ICN Pharmaceuticals; Antisense oligonucleotide 16967Latest Information Update: 19 Jul 2018
Price :
$50 *
At a glance
- Originator Valeant Pharmaceuticals International
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action CD44 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer metastases; Malignant melanoma
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 02 Jun 2000 New profile
- 02 Jun 2000 Preclinical development for Cancer metastases in USA (Unknown route)